Bayer Surpasses Q2 Earnings and Sales, Upgrades 2025 Forecast

Bayer AG’s Strong Q2 2025 Performance

Bayer AG reported strong second-quarter results for 2025, with core earnings of 35 cents per American Depositary Receipt (ADR), exceeding expectations. This performance was well above the Zacks Consensus Estimate of 25 cents per ADR. The company also saw a significant increase in core earnings, which rose to €1.23 per share, reflecting a 30.9% year-over-year growth. This improvement was driven by lower interest expenses and reduced tax obligations.

Total sales for the quarter reached $12.18 billion (€10.7 billion), slightly below the previous year's figures on a reported basis. However, this result still surpassed the Zacks Consensus Estimate of $12 billion. On a currency and portfolio-adjusted basis, sales showed a modest increase of 0.9% compared to the same period last year.

Over the first half of 2025, Bayer's shares have surged by 63.1%, outperforming the industry, which saw a decline of 3.7%.

Breakdown of Segment Performance

Bayer operates under three main segments: Crop Science, Pharmaceuticals, and Consumer Health. Each segment contributed to the overall performance in different ways.

Crop Science

Crop Science sales increased by 2.2% to €4.8 billion, primarily due to growth in Corn Seed & Traits. Sales in this area surged by 29.5%, fueled by higher planted areas and price increases across North America, Latin America, and Asia/Pacific. Herbicides sales rose by 1.4%, mainly due to higher volumes in Latin America and Europe/Middle East/Africa for non-glyphosate-based products. However, Fungicide sales declined by 5.7% due to generic pricing pressure and lower volumes in North America.

Soybean Seed & Traits sales dropped by 18.1% due to regulatory issues in the U.S., while Insecticides sales fell by 13.1% because of the expiration of Movento registration in Europe. Cotton Seed sales decreased by 25.5% due to regulatory challenges in the U.S., but Vegetable Seeds sales increased by 1.1% thanks to higher prices.

Pharmaceuticals

Pharmaceuticals sales grew by 0.6% to €4.47 billion. Key products like Nubeqa (for cancer) saw a 50.5% increase in sales to €546 million, driven by gains in all regions, especially the U.S. and EU. Kerendia sales jumped by 67.1%, largely due to strong volume growth in the U.S. and China.

Eylea, an ophthalmology drug, recorded a 4.3% sales increase to €862 million, supported by higher volumes in France and the launch of Eylea 8 mg. However, Xarelto, an oral anticoagulant co-developed with Johnson & Johnson, saw a 27.1% drop in sales to €650 million due to competition from generics, particularly in the EU and Japan.

Consumer Health

Consumer Health sales rose only slightly by 0.2% to €1.4 billion, impacted by a soft allergy season in North America and challenges in Asia/Pacific. Nutritionals sales declined by 7%, while Allergy & Cold business gained 5.7% from products like Claritin and Aspirin. Dermatology sales increased by 4.4%, driven by demand for Priorin and Bepanthen. Pain & Cardio sales were up by 1.4%, but Digestive Health declined by 3.8%.

Guidance and Pipeline Updates

Bayer has raised its 2025 sales guidance to €46-€48 billion, up from the previous range of €45-€47 billion. This adjustment reflects better-than-expected performance in the Pharmaceuticals segment during the first half of the year. The company also expects EBITDA before special items to be between €9.7-€10.2 billion, an increase from the earlier forecast of €9.5-€10 billion.

In terms of pipeline updates, several key drugs received approvals. Eylea was approved in China for treating neovascular age-related macular degeneration. Nubeqa received European Commission approval for metastatic hormone-sensitive prostate cancer. Kerendia was expanded for heart failure treatment, and applications for approval in other regions are ongoing. Elinzanetant was approved in the UK and Canada for menopause symptoms, but the FDA extended the review period for the U.S. application.

Additionally, Bayer submitted applications for gadoquatrane, an investigational contrast agent, in the U.S., Japan, and the EU for use in MRI scans.

Overall Outlook

Bayer delivered better-than-expected results in Q2 2025, with strong performances in Pharmaceuticals and Crop Science. The label expansions and new drug approvals should help drive future sales. However, litigation related to Roundup continues to impact the company's financials. With a Zacks Rank of #2 (Buy), Bayer remains a compelling investment opportunity for investors.